PREMIERE… At the Bârlad hospital, Covid-19 support, the administration of neutralizing monoclonal antibodies for SARS-CoV-2 started. The treatment with neutralizing monoclonal antibodies was administered for the first time, on October 25, to a 72-year-old patient, hospitalized in the Infectious Diseases Department of the Municipal Emergency Hospital “Elena Beldiman. The procedure went smoothly at the ATI department, under the guidance of the ATI primary care physician, Veaceslav Galit.
The patient who received this treatment met the criteria set out in the Order of 12 October on the protocol for the treatment of SARS-CoV-2 virus infection. The decision to administer neutralizing monoclonal antibodies to SARS-CoV-2 belongs to a committee of at least two doctors of Infectious Diseases. In this case, during the day of October 25, following the evaluation of the patient’s status, the team formed by Monica Aioane – primary care physician, respectively Luana Butiuc – primary care physician, decided that this treatment is appropriate.
“The patient had a mild form of COVID-19, but with great potential for aggravation in the absence of this treatment, this being in the first days after the onset of SARS-CoV-2 infection, the procedure being performed with her consent,” he said. specified the management of the Bârlad hospital.
Neutralized monoclonal antibodies have specificity for SARS-CoV-2 virus protein S and, like other antiviral medications, efficacy depends on administration as early as possible after the onset of the disease, no later than the first 7 days. Patients who may benefit from this treatment are those at significant risk of severe disease progression, this medication helping them to stop developing severe forms. According to the Order on the protocol for the treatment of SARS-CoV-2 virus infection, the eligibility criteria (EMA) – cumulative criteria: 1, 2, 3 and at least one of the risk factors are:
- signing informed consent;
- light forms SO_2> 93% without oxygen supplement;
- administration of monoclonal antibodies <7 days after the onset of symptoms;
- risk factors for severe evolution (priority is given to people with several risk factors): age> 65 years; BMI> 30 kg / m + 2; severe cardiovascular disease, NYHA heart failure 4, recent myocardial infarction, severe ischemic heart disease; COPD; type 1 diabetes; immunosuppressive therapy – biological therapies; organ or bone marrow transplant patients; patients with neoplasms or haematological diseases in therapy; AIDS.
—
